Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
Cagrilintide . acetate
90
CHF
CHF 90.00
In stock
AG-CP3-0047-M0011 mgCHF 90.00
AG-CP3-0047-M0055 mgCHF 270.00
AG-CP3-0047-M02525 mgCHF 810.00
BULK available!
Research Use Only (RUO). NOT ALLOWED FOR USE IN HUMANS.
| Product Details | |
|---|---|
| Synonyms | AM833; NN0174-0833 |
| Product Type | Chemical |
| Properties | |
| Formula |
C194H312N54O59S2 . C2H4O2 |
| MW | 4409.0 . 60.0 |
| Sequence |
{Eicosanedioic acid-γ-Glu}-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-NH2 (Disulfide bridge:Cys2-Cys7) |
| CAS | 1415456-99-3 (free acid) |
| Source/Host Chemicals | Synthetic. |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | White powder. |
| Solubility | Soluble in water (50mg/ml). |
| Endotoxin Content | ≤ 10EU/mg |
| InChi Key | ZVFSCEVVTIADGE-SXJCWIKGSA-M |
| Smiles | O=C(N)[C@H]1N(C([C@H]([C@H](O)C)NC([C@H](CC(N)=O)NC([C@H](CO)NC(CNC([C@H](C(C)C)NC([C@H](CC(N)=O)NC([C@H]([C@H](O)C)NC([C@H]2N(C([C@H]3N(C([C@H](CC(C)C)NC([C@H]([C@@H](C)CC)NC([C@H]4N(C(CNC([C@H](CC5=CC=CC=C5)NC([C@H](CC(N)=O)NC([C@H](CC(N)=O)NC([C@H](CO)NC([C@H](CO)NC([C@H](CC6=CNC=N6)NC([C@H](CCCNC(N)=N)NC([C@H](CC(C)C)NC([C@H](CC7=CC=CC=C7)NC([C@H](CCC(O)=O)NC([C@H](C)NC([C@H](CC(C)C)NC([C@H](CCCNC(N)=N)NC([C@H](CCC(N)=O)NC([C@H]([C@H](O)C)NC([C@H](C)NC([C@H](CSSC[C@@H]8NC([C@H](CCCCN)NC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)NC([C@H]([C@H](O)C)NC([C@H](C)NC([C@H]([C@H](O)C)NC([C@H](CC(N)=O)NC8=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CCC4)=O)=O)=O)CCC3)=O)CCC2)=O)=O)=O)=O)=O)=O)=O)=O)CCC1.CC([O-])=O |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Keep cool and dry. |
| Use/Stability | Stable for at least 1 year after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
-
Cagrilintide is a novel long-acting nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist.
-
Cagrilintide is a stable synthetic peptide acylated amylin analog. Natural amylin is a pancreatic hormone that induces satiety.
-
Cagrilintide binds human, mouse and rat amylin receptors and is used in studies of obesity and type 2 diabetes (T2D) and is designed enhancing energy expenditure and fat metabolism and decreasing food intake.
-
Cagrilintide is now being developed in combination with the GLP-1 agonist semaglutide as "CagriSema" to achieve sustained weight loss in persons with overweight and obesity. Amylin, released with insulin from beta cells in the pancreas, induces its satiating effect via both the homoeostatic and hedonic regions of the brain. Semaglutide, a GLP-1 receptor agonist, reduces appetite via GLP-1 receptors in the hypothalamus and increases the production of insulin, and reduces glucagon secretion, delaying gastric emptying. These separate, but related mechanisms of action of an amylin-analog and a GLP-1 receptor agonist appear to have an additive effect on appetite reduction.
-
Cagrilintide comprises a 37 amino acid linear synthetic peptide conjugated to a C20 fatty diacid through a hydrophilic linker at the lysine residue at position 1. Due to this moiety, the compound is highly bound to albumin in the plasma which prolongs its half-life. The N-terminus of the amylin peptide is predicted to form a loop, stabilized by a disulfide bond, that points out of the TM area, thereby tolerating N-terminal lipidation.
Product References
-
AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists: M.F. Fletcher, et al.; JPET 377, 417 (2021)
-
Development of Cagrilintide, a Long-Acting Amylin Analogue: T. Kruse, et al.; J. Med. Chem. 64, 11183 (2021)
-
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial: D.C.W. Lau, et al.; The Lancet 398, 2160 (2021)
-
823-P: The Long-Acting Dual Amylin and Calcitonin Receptor Agonist KBP Has Increased Efficacy on Weight Loss and Glucose Control Compared with Cagrilintide in Obese and Diabetic Rats: A.Z. Larsen, et al.; Diabetes 71, 823-P (2022)
-
Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity: A.M. D'Ascanio, et al.; Cardiol. Rev. 32, 83 (2024) (Review)
Related Products
